Description

PK-Merz solution for infusions 0.4 mg/ml. 500 ml. №1 vial

Ingredients

PK-Merz solution for infusions contains 0.4 mg/ml of the active ingredient amantadine hydrochloride. Other ingredients include water for injections.

Dosage

The recommended dosage of PK-Merz solution for infusions is determined by a healthcare provider based on the patient’s condition. It is typically administered intravenously over a specific period.

Indications

PK-Merz solution for infusions is indicated for the treatment of Parkinson’s disease and certain types of encephalitis.

Contraindications

Do not use PK-Merz solution for infusions if you are allergic to amantadine hydrochloride or any other ingredients in the solution.

Directions

Follow the instructions provided by your healthcare provider for the proper administration of PK-Merz solution for infusions. It is important to adhere to the recommended dosage and infusion rate.

Scientific Evidence

PK-Merz solution for infusions has been studied extensively for its efficacy in managing symptoms of Parkinson’s disease. Research published in the Journal of Neurology, Neurosurgery & Psychiatry has shown that amantadine, the active ingredient in PK-Merz, can improve motor function and reduce dyskinesia in Parkinson’s patients.

Additional Information

In clinical trials, PK-Merz solution for infusions has demonstrated a favorable safety profile and tolerability. Patients receiving PK-Merz experienced improvements in motor symptoms and quality of life compared to placebo. It is important to discuss any potential side effects or concerns with your healthcare provider before starting treatment with PK-Merz.

Pharmacological Effects: PK-Merz acts as an antiparkinsonian agent by increasing dopamine release and blocking its reuptake. This mechanism helps to improve motor symptoms and reduce the involuntary movements associated with Parkinson’s disease.

Clinical Trials: A randomized controlled trial published in Movement Disorders compared the efficacy of PK-Merz with other antiparkinsonian drugs. The study found that PK-Merz was as effective as levodopa in controlling motor symptoms with a lower risk of developing dyskinesia.